Vulvar carcinoma

Summary

Vulvar carcinoma (MONDO:0005215) is a cancer (an umbrella term covering 9 Mondo subtypes) and 172 clinical trials. Top therapeutic interventions include indocyanine green acid form, bleomycin, and fludarabine phosphate. A subtype of vulva cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 1 000 000 (Worldwide) [Orphanet-validated]
• Umbrella term: 9 Mondo subtypes
• Clinical trials: 172

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.86	Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	vulvar carcinoma
Mondo ID	MONDO:0005215
EFO	EFO:0002921
Orphanet	494418
DOID	DOID:1294
NCIT	C4866
SNOMED CT	447882007
UMLS	C0677055
MedGen	146159
GARD	0009349
Anatomy (UBERON)	UBERON:0000997
Is cancer (heuristic)	yes

Also known as: cancer of the vulva · cancer of vulva · carcinoma of mammalian vulva · carcinoma of the vulva · carcinoma of vulva · mammalian vulva carcinoma · vulva cancer · vulva carcinoma · vulvar cancer · vulvar carcinoma

Data availability: 1 cell line.

Disease family

This is a subtype of vulva cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › vulva cancer › vulvar carcinoma

Related subtypes (7): labium majus cancer, labia minora cancer, paraurethral gland cancer, vulvar melanoma, clitoris cancer, vulva sarcoma, mixed germ cell tumor of vulva

Subtypes (9): labia minora carcinoma, labia majora carcinoma, bartholin gland carcinoma, vulva basal cell carcinoma, vulvar seborrheic keratosis, vulvar adenocarcinoma, vulvar squamous cell carcinoma, clitoral carcinoma, vulvar neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Carboplatin	Phase 2
Paclitaxel	Phase 2
Pembrolizumab	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 172.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	93
PHASE2	41
PHASE3	16
PHASE1	16
PHASE1/PHASE2	4
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT04422366	PHASE3	RECRUITING	Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04895020	PHASE3	RECRUITING	Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
NCT06476639	PHASE3	NOT_YET_RECRUITING	A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer
NCT00003325	PHASE3	COMPLETED	Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
NCT00006096	PHASE3	TERMINATED	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva
NCT00028951	PHASE3	COMPLETED	Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva
NCT00033605	PHASE3	COMPLETED	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
NCT00543543	PHASE3	COMPLETED	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
NCT00577317	PHASE3	TERMINATED	Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer
NCT00898352	PHASE3	COMPLETED	Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
NCT00943722	PHASE3	COMPLETED	A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
NCT01047345	PHASE3	COMPLETED	A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
NCT02997553	PHASE3	COMPLETED	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
NCT03158220	PHASE3	COMPLETED	Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
NCT04425291	PHASE3	COMPLETED	Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05372016	PHASE3	COMPLETED	Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT02628067	PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03403465	PHASE2	ACTIVE_NOT_RECRUITING	Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
NCT04141449	PHASE2	ACTIVE_NOT_RECRUITING	A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
NCT04430699	PHASE2	ACTIVE_NOT_RECRUITING	Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04708470	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
NCT05076942	PHASE2	RECRUITING	Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05395962	PHASE2	RECRUITING	Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
NCT05639972	PHASE1/PHASE2	RECRUITING	E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
NCT05686226	PHASE2	RECRUITING	E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT05903833	PHASE2	RECRUITING	Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT05905315	PHASE2	RECRUITING	Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC
NCT05932212	PHASE2	RECRUITING	AK104 for Recurrent or Metastatic Vulvar Cancer
NCT05969860	PHASE2	RECRUITING	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT05979610	PHASE2	RECRUITING	Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
NCT06023862	PHASE2	RECRUITING	A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06492070	PHASE2	RECRUITING	Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
NCT06677190	PHASE2	RECRUITING	Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
NCT06686043	PHASE2	RECRUITING	HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT06715592	PHASE2	ACTIVE_NOT_RECRUITING	ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study
NCT07101848	PHASE2	NOT_YET_RECRUITING	A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER
NCT07290894	PHASE2	RECRUITING	Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
NCT07407647	PHASE2	RECRUITING	Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INDOCYANINE GREEN ACID FORM	4	5
BLEOMYCIN	4	2
FLUDARABINE PHOSPHATE	4	2
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	4	2
TIVOZANIB	4	2
BELZUTIFAN	4	1
CICLOPIROX	4	1
CILOSTAZOL	4	1
DOSTARLIMAB	4	1
FONDAPARINUX SODIUM	4	1
NELFINAVIR	4	1
OCTREOTIDE ACETATE	4	1
PRASTERONE	4	1
BINTRAFUSP ALFA	3	1
CADONILIMAB	3	1
ENTINOSTAT	3	1
FIBRIN	3	1
PERFLUBUTANE	3	1
TRIAPINE	3	1
EDODEKIN ALFA	2	1
VUDALIMAB	2	1
CHEMBL4084635	0	1
COD LIVER OIL	-1	1